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Abstract: The prominence of the PI3K-Akt signaling pathway in several tumors indicates a 
relationship with tumor grade and proliferation. Critical cellular processes are driven through 
this pathway. More detailed knowledge of the pathogenesis of tumors would enable us to 
design targeted drugs to block both membrane tyrosine kinase receptors and the intracellular 
kinases involved in the transmission of the signal. The newly approved molecular inhibitors 
sunitinib (an inhibitor of vascular endothelial growth factor receptor, platelet-derived growth 
factor receptor, and other tyrosine kinase receptors), sorafenib (a serine–threonine kinase inhibi-
tor that acts against B-Raf) and temsirolimus (an mTOR inhibitor) shown clinical activity in 
advanced kidney cancer. Chronic myeloid leukemia has changed its natural history thanks to 
imatinib and dasatinib, both of which inhibit the intracellular bcr/abl protein derived from the 
alteration in the Philadelphia chromosome. Intracellular pathways are still important in cancer 
development and their blockade directly affects outcome. Cross-talk has been observed but 
is not well understood. Vertical and horizontal pathway blockade are promising anticancer 
strategies. Indeed, preclinical and early clinical data suggest that combining superficial and 
intracellular blocking agents can synergize and leverage single-agent activity. The implication 
of the Akt signaling pathway in cancer is well established and has led to the development of 
new anticancer agents that block its activation.
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Introduction
The phosphatidylinositol 3-kinase (PI3K)-Akt pathway is situated in downstream 
tyrosine kinase receptors (TKRs) and regulates essential cellular functions such as 
proliferation, growth, and survival.1 Akt is a serine/threonine kinase that belongs to 
the AGC (protein kinase A/protein kinase G/protein kinase C-like) family of protein 
kinases. Because it shows high homology with protein kinases A and C, Akt is also 
referred to as protein kinase B (PKB).
PI3K-Akt signaling is frequently altered in human cancers.1 We describe the main 
downstream effectors of PI3K-Akt pathway involved in its proliferative and survival 
responses. We also examine PI3K-Akt signaling pathway alterations associated with 
human cancers and their implications in the development of target-based anticancer 
drugs.
Structure and activation of Akt kinase
In mammals, three Akt genes encode for the isoforms Akt1 (PKBα), Akt2 (PKBβ), 
and Akt3 (PKBγ), and they all have a similar structure and size.1 Akt isoforms contain OncoTargets and Therapy 2009:2 136
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a pleckstrin homology (PH) domain in the N-terminus, a 
central catalytic domain with kinase activity, and a C-terminal 
regulatory domain (Figure 1A). The PH domain binds phos-
phatidylinositol-3,4,5-trisphosphate (PIP3). Akt also contains 
two main phosphorylation sites: Threonine308 (Thr308) in 
the kinase domain and Serine473 (Ser473) in the regulatory 
domain.1
After binding their growth factors, TKRs can directly or 
indirectly, via an adaptor molecule such as IRS1, activate 
PI3K, a molecular complex composed of a p85 regulatory 
subunit and a p110 catalytic subunit.1 Phosphotyrosine 
residues on the cytoplasmic tail of the activated TKRs or on 
their associated adaptor proteins recruit PI3K complex to the 
membrane by binding its p85 regulatory subunit and remov-
ing the inhibitory effect of p85 (Figure 1B). The GTPase 
RAS can also directly activate PI3K through the binding to 
its p110 catalytic subunit. Once on the cell membrane, PI3K 
phosphorylates phosphatidylinositol and converts inositol 
4,5 biphosphate (PIP2) into PIP3. Subsequently, Akt and the 
serine/threonine kinase PDK1 translocate to the membrane 
where they interact with PIP3 through their PH domain. This 
interaction promotes conformational changes in Akt, resulting 
in exposure of Thr308 and Ser473. Thr308 is phosphorylated 
by PDK1, leading to the stabilization of Akt.1 The second 
phosphorylation event associated with Akt activation occurs 
at Ser473, and is required for full activation (Figure 1B). 
Recently, a second protein complex with kinase activity, the 
mammalian target of rapamycin (mTOR)-rictor complex has 
been shown necessary for this Ser473 phosphorylation of 
Akt.2 Therefore, Akt activation implies a dual mechanism: 
translocation to the plasma membrane after PI3K activation 
followed by two phosphorylation events mediated by PDK1 
and mTOR-rictor complex. This pathway is also negatively 
regulated at the level of PIP3 by phospholipid phosphatases, 
such as the phosphatase and tensin homologue PTEN.3
Biological functions of Akt signaling
Although, differences in the signaling capabilities of Akt 
isoforms have been established, as we review below, the 
biological consequences of Akt activation relevant for cancer 
progression are survival, proliferation, growth, angiogenesis, 
and metastasis (Figure 2).3–5
Akt activation and cell survival
Promotion of cell survival is the most studied function of the 
Akt pathway. Akt develops its anti-apoptotic role through 
phosphorylation of downstream substrates that control the 
apoptotic machinery.
Akt indirectly downregulates activation of the pro-apoptotic 
protein p53 by activating Mdm2 (murine double minute-2), 
which promotes p53 degradation.5 In response to genetic dam-
age, p53 stimulates the expression of pro-apoptotic proteins 
to ensure that damaged genetic information is not passed to 
descending cells. Thus, tumor cells develop the ability to sur-
vive after not repairing DNA damage through activation of the 
PI3K-Akt pathway (Figure 2).
Additionally, Akt signaling leads to transcription of 
NF-κB (nuclear factor κB) anti-apoptotic target genes. Akt 
activates IKK (IκB kinase), which induces degradation of 
IκB (the NF-κB inhibitor). The unmasked NF-κB can then 
enter the nucleus and activate the expression of pro-survival 
target genes (Figure 2).3,5
Akt also restores the anti-apoptotic function of BCL-XL 
through inactivation of its inhibitor, BAD (Figure 2).3,5
The inactivation of the Forkhead family of transcription 
factors by Akt inhibits the transcription of their death target 
genes (Fas-ligand, Bim, and immunoglobulin-binding protein-1 
[IGBP-1]; Figure 2).3,5
Akt also phosphorylates p21/WAF, which increases p21 
stability. Elevated p21 protein levels have been observed 
in various aggressive tumors linked to chemoresistance. 
Glioblastoma cell lines with active Akt showed higher p21 
stability and were more resistant to paclitaxel.6
Akt activation and proliferation
Akt signaling can also affect proliferation by regulating 
proteins of the cell-cycle machinery.
Akt blocks transcription of the cell cycle inhibitor p27/
KIP1 by inactivating Forkhead transcription factors.3 It also 
inhibits the anti-proliferative effects of p21 and p27, thus 
impairing their entry into the nucleus.3
Furthermore, Akt inhibits glycogen synthase kinase-3 
(GSK3), thus Akt directly prevents β-catenin degradation. 
Once inside the nucleus, stabilized β-catenin activates expres-
sion of pro-proliferative target genes such as cyclin D1 and 
c-Myc (Figure 2).3,5
Akt-mTOr activation and cell growth, 
angiogenesis, and metastasis
The target of rapamycin (TOR) is an evolutionary conserved 
Ser/Thr kinase that represents the catalytic subunit of two 
distinct signaling complex: the mTOR-ractor complex 
(mTOR complex 1) and mTOR-rictor and SIN1 complex 
(mTOR complex 2).7 In the presence of growth-promoting 
signals such as nutrients and growth factors, mTOR complex 1 
promotes growth by upregulation of the protein synthesis8 OncoTargets and Therapy 2009:2 137
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and it also induces the biogenesis of the machinery for the 
protein synthesis, the ribosome.9 The function of mTOR 
complex 2 is less well defined, it is known that is required for 
phosphorilation of Akt2 (Figure 3) and it is also involved in 
actin cytoskeleton reorganization and cell survival.10 mTOR 
complex 1 is inhibited by rapamycin and its derivates everoli-
mus and tenserolimus.7 Therefore, rapamycin analogs are not 
able to block mTOR complex 2 effects. In fact, in response to 
these drugs, an increase in Akt phosphorylation is detected in 
tumor byopsies and tumor samples from animal models as a 
result of a feedback activation loop of Akt signaling through 
an IGF-1R-dependent mechanism.11–13
The TSC1/TSC2 (tuberous sclerosis complex) protein 
complex is involved in the negative regulation of the mTOR 
kinase (Figures 2 and 3). mTOR is activated by the GTPase 
Rheb which in turn is controlled by the TSC1/TSC2 complex. 
As a result of growth-stimulating signals, Akt phosphorylates 
TSC2 and causes the dissociation of the TSC1/TSC2 complex. 
This dissociation reduces the inhibitory function of the TSC1/
TSC2 complex on GTPase Rheb thus enabling the activation of 
the mTOR complex 1. mTOR complex 1 controls cell growth 
in part by phosphorylating of the kinase 70 S6K1 (S61) and the 
protein 4EBP-1 (4E-binding protein 1), both of them known 
regulators of protein synthesis (Figures 2 and 3). p70 S6K1 
is activated by two phosphorylation events: phosphorylation 
on Ser473 by mTOR complex 2 and on Thr308 by PDK1.7,14 
Subsequently, phosphorylated p70 S6K1 activates the ribo-
somal protein S6 that stimulates the translation of 5´-TOP 
messenger ribonucleic acids (mRNAs). These mRNAs encode 
for proteins of the translation machinery, resulting in a high 
protein translation rate (Figures 2 and 3).
Besides activating p70 S6K1, mTOR controls the 
association of the translation initiation factor eIF-4E with 
its inhibitor 4EBP-1. mTOR phosphorylates the 4EBP-1 
inhibitor. Thus, eIF-4E can be released from 4EBP-1 and 
stimulate the translation of the CAP-dependent mRNAs 
(Figure 3) that encode for proteins with key cellular functions 
such as hypoxia-inducible factor-α (HIF-α), a transcrip-
tion factor that controls the expression of approximately 
30 hypoxia-regulated genes.7 These target genes include 
pro-angiogenic genes, such as VEGF (vascular endothelial 
growth factor), PDGF (platelet-derived growth factor), and 
genes that encode proteases associated with local invasion 
such as matrix metalloproteinase 9 (MMP9). In fact, active 
p70 S6K1 promotes invasion in ovarian cancer cell lines by 
stimulating metalloproteinase MMP9 expression.15
VEGF is considered the most potent stimulator of angio-
genesis within tumors. HIF-α protein levels are controlled by 
the von Hippel–Lindau (pVHL) protein complex.16 Absence 
and/or inactivation of pVHL has been documented in many 
tumors, thus leading to HIF-α accumulation. Subsequent 
high VEGF expression promotes angiogenesis.15 PDGF is 
considered at least as important as VEGF in the stabiliza-
tion and maturation of newly formed vessels. In fact, PDGF 
over-function may also cause tumors.
Akt isoforms and specific biological 
functions
It has been suggested that different Akt isoforms show differ-
ent signaling capabilities.17 Different roles for Akt isoforms in 
the physiological response to insulin (the storage of nutrients 
in muscle and adipose tissues) has been already suggested. In 
fact, Akt2 levels increase during the differentiation of cells 
into insulin-responsive adipocytes, whereas the expression 
of Akt1 decreases in these cells.18,19 In addition, Akt2 is 
placed in the plasmatic membrane near the insulin-responsive 
GLUT4 glucose transporter whereas Akt1 is placed mainly 
in the cytosolic compartment. Phosphorylation of GLUT4 
transporter by Akt2 has been also reported.20,21 These data 
suggest that Akt2 might be involved in insulin-induced 
GLUT4 translocation and glucose uptake.
Additional data supporting a different role for Akt iso-
forms came from transgenic mice. An impairment in insulin 
ability to maintain normal glucose homeostasis is known 
as insulin resistance and predisposes to the development of 
type 2 diabetes, hypertension, and cardiovascular disease.22 
Accordingly, mice lacking Akt2 displayed insulin resistance 
and a diabetes-like syndrome.23 Mice lacking Akt1 showed 
normal glucose homeostasis but were small throughout 
life,24,25 which suggests that Akt1 may be mainly involved 
in control of growth and proliferation.
The knowledge of the biological functions mediated 
by each Akt isoform may be useful to predict the toxici-
ties that may be associated with those inhibitors that target 
a specific Akt isoform or with pan-Akt inhibitors. As we 
review below, high grade hyperglycemia has been already 
observed in animal models and clinical trials with novel 
Akt inhibitors.
Akt activation in cancer
The PI3K-Akt pathway is often aberrantly activated in 
cancer (see Table 1) due to genetic and epigenetic altera-
tions. It is also associated with poor prognosis in a variety 
of tumor types (pancreas, gastric, breast, tongue, glioma, 
non-small cell lung cancer [NSCLC], and others) and resis-
tance to chemotherapy, radiotherapy, and/or target-based OncoTargets and Therapy 2009:2 138
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anticancer agents.26,27 Alterations in signaling proteins 
placed upstream PI3K and genetic alterations in genes 
that encode for proteins belonging to the pathway such as 
PTEN deletions and “hot-spot” mutations in PI3K28 lead to 
an aberrant activation of this pathway and are associated 
with the development and progression of human cancers.
Alterations upstream of Pi3K-Akt
The most common alterations upstream of PI3K-Akt include 
amplification/activating mutations, an increase in the expres-
sion of genes that encode for TKRs, and higher expression of 
genes that encode for growth factors. Activating mutations 
in intracellular signaling proteins placed upstream of Akt 
(eg, Ras) also promote the aberrant activation of Akt signal-
ing in cancer cells, thus leading to inappropriate survival and 
proliferation (Figure 3).
The PI3K/Akt/mTOR and the Ras/Raf/MAPK pathways 
are commonly activated by TKRs, and there is a large 
amount of cross-talk between them (Figure 1D).29 Indeed, 
defects in the signaling molecules belonging to one pathway 
may also alter the other pathway through these interconnec-
tions. Due to this cross-talk, gain of function mutations in 
Ras that occur in many tumors (90% of pancreas, 50% of 
colon, 50% of thyroid, 30% of lung cancers) could also be 
associated with an increase in Akt signalling.29 The Bcr-Abl 
fusion protein, generated after chromosomal translocation 
associated with chronic myeloid leukaemia, is also able 
to constitutively activate PI3K-Akt and Ras/Raf/MAPK 
pathways (Figure 3).30
Alteration in Pi3K or Akt
Several isoforms of the PI3K family are implicated in disease. 
In particular, members of the class 1A PI3Ks (heterodimers 
with a p85 regulatory and a p110 catalytic subunit). Many 
tumors show activating mutations in the genes that encode 
for the catalytic and regulatory subunits of PI3K.3,27
Akt amplification or overexpression occur at the mRNA 
level in various tumor cell lines and in a number of human 
cancers (see Table 1). Amplification in the Akt gene has been 
associated with poor prognosis and resistance to radiotherapy 
and/or chemotherapy.3 Nevertheless, activation of Akt 
isoforms by phosphorylation appears to be more clinically 
significant than Akt amplification or overexpression.31
Alteration in phosphatases belonging 
to the pathway
Two protein phosphatases, PTEN and SHIP (SH2 contain-
ing inositol phosphatase), negatively regulate Akt activation 
by blocking Akt translocation to the plasma membrane 
(Figure 1C).
PTEN prevents elevated levels of PIP3 by dephosphory-
lating its 3´ position. Thus, PTEN leads to the blockade of Akt 
translocation to the plasma membrane (Figure 1C).3 PTEN 
is one of the most frequently mutated or deleted genes in 
human cancer (see Table 1),32 and its absence in tumors cor-
relates strongly with activation of Akt.3 Pre-clinical models 
showed that mice with conditional tissue disruption of PTEN 
develop tumors in the affected tissue.3 Furthermore, PTEN 
loss also predicts for resistance to anticancer drugs such as 
the anti-HER2 (human epidermal growth factor receptor-2) 
agent trastuzumab.33
SHIP is another negative regulator of Akt that dephos-
phorylates PIP3 at the 5´ position (Figure 1C). Loss of SHIP 
can also occur in cancer cells. Peripheral T cells isolated 
from acute and chronic T cell leukemia/lymphoma patients 
showed lower levels of PTEN and SHIP, which correlates 
with upregulation of Akt signaling.34
In addition, Akt phosphorylation is negatively controlled 
by carboxyl-terminal modulating protein (CTMP), which acts 
downstream of PTEN and SHIP, at the plasma membrane 
level, and binds specifically to the carboxyl-terminal regulatory 
domain of Akt. CTMP reduces the activity of Akt by inhibiting 
its phosphorylation at Ser473 and Thr308 (Figure 1C). Loss 
of CTMP by hypermethylation of its promoter has also been 
detected in glioblastoma and glioma cell lines.35
Akt pathway deregulation 
in selected cancers
As reviewed above, isolated or combined defects in PI3K/Akt 
pathway components and/or molecules in interconnected 
signaling cascades are associated with many cancers and 
lead to an increase in Akt signaling. Aberrant Akt activation 
mediates the signals for survival, proliferation, angiogenesis, 
and/or metastasis in tumor cells. Furthermore, resistance to 
cancer therapies is often associated with abnormal activation 
of this pathway.
Here, we focus on the PI3K-Akt alterations associated 
with specific tumors (Table 1).
renal cell carcinoma
The most frequent histopathologic variant of renal cell car-
cinoma (RCC) is the clear-cell type (75% of cases).36
In familial and in most sporadic (40%–60%) clear-cell 
RCC tumors, pVHL is disrupted.36 and the PI3K-Akt-mTOR 
pathway plays a critical role in survival, proliferation, and 
angiogenesis.16OncoTargets and Therapy 2009:2 139
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Figure 1 Akt structure and regulation. A) Akt structure. There are three Akt isoforms (Akt1/2/3), all of which share a similar structure and size. These isoforms contain a 
PH (pleckstrin homology) domain in the N-terminus, a central catalytic domain with kinase activity, and a regulatory domain in the C-terminus. The PH domain binds inositol 
triphosphate (PiP3). Akt also contains two main phosphorylation sites: one threonine in the kinase domain (Thr308) and one serine the regulatory domain (Ser473). B) Dual 
regulatory mechanism of Akt activation: translocation to the plasma membrane followed by phosphorylation. After their activation by specific growth factors (GF), tyrosine 
kinase receptors (TKrs) can promote the activation of the Pi3K complex (p85 plus p110 subunits) directly or by means of the small GTPase monomeric protein ras. Active 
Pi3K converts inositol biphosphate (PiP2) into PiP3, which triggers the translocation of Akt and PDK1 to the plasma membrane, where they interact with PiP3 through their 
PH domain. Subsequently, Akt is phosphorylated by PDK1 in its Thr308 residue and by other kinases such as mTOr in its Ser473 residue. C) Negative regulation of Akt activa-
tion. The phosphatases PTeN and SHiP (in grey) promote the blockade of Akt translocation to the plasma membrane by dephosphorylation of PiP3 (in red) in PiP2 (in green). 
Additionally, CTMP (in blue) negatively regulates Akt activation preventing its phosphorylation in Ser473 and Thr308.OncoTargets and Therapy 2009:2 140
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The transcription factor, HIF, which controls the expression 
of hypoxia-inducible genes, is a heterodimer of two subunits 
(HIF-α and HIF-β). In each cell, HIF-β is constitutively 
expressed, whereas the intracellular amount of HIF-α is highly 
controlled at two levels: PI3k/Akt signaling through mTOR 
at the translational level and pVHL at the post-translational 
level.36,37
pVHL is a component of a ubiquitin ligase complex that 
promotes the destruction of specific cellular proteins through 
proteosome degradation. In normal tissue, under normoxic 
conditions, pVHL recognizes and binds hydroxylated 
HIF-α, which, once bound by pVHL, will be ubiquitinated 
to be degraded by the proteosome. However, under hypoxic 
conditions, HIF-α, is not hydroxylated, pVHL is not able 
to recognize HIF-α and, consequently, is not degraded. 
Stabilized HIF-α is translocated to the nucleus, binds with 
HIF-β, and forms a heterodimer that promotes expression of 
hypoxia-response target genes.37
pVHL is lost or inactivated in most clear-cell RCC, and 
HIF-α, although hydroxylated, is not degraded. Accumulated 
HIF-α, leads to increased expression of hypoxia-response 
genes.37,38 HIF-inducible genes are associated with tumoro-
genesis because they are involved mainly in angiogenesis 
(VEGF, PDGF, others), proliferation and survival (transform-
ing growth factor alpha [TGF-α], insulin-like growth factor 2 
[IGF2], and others), metabolism, and pH regulation.37,38
The characterization of PI3K-Akt-mTOR in metastatic 
RCC patients using the UCLA RCC tissue array showed that 
loss of PTEN increased in all RCC patients with a greater loss 
in clear-cell tumors and sarcomatoid tumors. The presence of 
active Akt (pAkt) was greatest in collecting duct carcinoma 
followed by clear-cell carcinoma and loss of PTEN correlated 
with pAkt (p = 0.028) and HIF-α expression (p  0.0001). 
Active p70 S6K (pS6K) was also highly expressed by sarco-
matoid and clear-cell tumors (higher expression in high-grade 
and in high-stage).36 The mTOR inhibitor temsirolimus has 
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Figure 2 Biological functions of Akt signaling. Most of the cellular responses controlled by Akt are related to cancer. Once active,   Akt regulates the activity of other intracellular 
signaling proteins that will trigger changes in the expression of specific genes that encode for proteins involved in cell survival (in grey) or proliferation/cell cycle (in yellow). 
Additionally, by activation of the mTOR protein, Akt will enhance the translation of specific mRNAs. TOP-dependent mRNAs that encode for proteins involved in ribosome 
biogenesis and also the translation of CAP-dependent mrNAs that encode for proteins with key cellular functions such as angiogenesis and metastasis (in red-blue).OncoTargets and Therapy 2009:2 141
Akt as a promising therapeutic target in cancer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
recently shown efficacy in non-clear–cell RCC histologic 
subtypes.39 One proposed resistance mechanism for mTOR 
inhibition is the compensatory upregulation of Akt through 
the activation of the IGF receptor (IGF-1R) pathway as we 
will explain in the last section of this review. Accordingly, 
preclinical data showed by Holland and colleagues estab-
lished a rationale for the combination of therapies that target 
Akt and mTOR in RCC patients.40
Additionally, immunohistochemical analyses have also 
revealed that no patient who had low expression of pS6K or 
pAkt was a responder to this mTOR inhibitor.41 Pre-clinical 
assays with RCC cell lines have also shown that a loss of 
pVHL sensitized cells to temsirolimus, both in vitro and in 
mouse xenograft models, suggesting that loss of pVHL could 
be a predictive marker of the response to mTOR blockade.42 
Furthermore, PTEN-deficient tumor cell lines with high levels 
of pAkt were also more sensitive to the effects of temsirolimus 
in vitro.43 In this molecular scenario, the Akt pathway is a 
promising target in the treatment of metastatic RCC. In fact, 
the mTOR inhibitor temsirolimus has been already approved 
for the first line treatment of poor risk advanced RCC patients44 
and clinical trials with the mTOR inhibitor everolimus are cur-
rently underway to show its efficacy in RCC patients.45
Breast cancer
Hormone receptor- and HER2-positive breast cancer cur-
rently account for 75%–80% and 15%–20% of breast cancer 
cases, respectively, with about half of HER2-positive cases 
co-expressing hormone receptors. The remaining 10%–15% of 
breast cancer cases do not express HER2 and hormone recep-
tors and are called triple-negative breast cancers.46 Evidence 
shows PI3K pathway aberrations in breast tumors and suggests 
that this pathway may play a distinct role in the pathogenesis 
of different breast cancer molecular subtypes.
The analysis of 64 hormone receptor-positive-Her2-
negative breast cancer samples from patients with stage I to 
III tumors managed with hormonotherapy ± chemotherapy 
showed that the activation of the PI3K/Akt pathway was 
higher in those tumors with less hormone receptor levels and 
was also associated with adverse outcome.47
Recently, a genomic analysis of PIK3CA, PTEN, and 
Akt mutations in a collection of 547 breast cancer samples 
showed that PIK3CA mutations were more common in hor-
mone receptor-positive (34.5%) and HER2-positive (22.7%) 
than in triple-negative tumors (8.3%). Akt1 (1.4%) and 
PTEN (2.3%) mutations were restricted to hormone recep-
tor-positive cancers. However, PIK3CA mutations did not 
have a significant effect on outcome after adjuvant tamoxifen 
therapy in a population of 157 hormone receptor-positive 
breast cancer patients.48
HER2 overexpression in breast cancer is associated with a 
high recurrence rate, poor survival, and resistance to chemo-
therapy and endocrine therapy.49,50 PI3K/Akt and Ras/MAPK 
pathways are the major mediators of HER2 signaling.51 
Accordingly, tumor cells in which HER2 is overexpressed 
exhibit constitutive Akt activity.52 Furthermore, immunohisto-
chemical analysis of breast cancer samples indicated a possible 
role of PI3K/Akt/mTOR signaling in HER2-mediated breast 
cancer progression and has suggested its association with poor 
disease-free survival. Additionally, it has been suggested that 
the anti-HER2 agent trastuzumab depends on the intact PTEN 
for its action in HER2 overexpressing breast cancer cell lines 
and that the loss of PTEN predicts for trastuzumab resistance.33 
Therefore, Akt blockade could represent a promising strategy 
to treat breast cancer patients who are trastuzumab resistant.53,54 
Moreover, an oral dual tyrosine kinase inhibitor (TKi) of epi-
dermal growth factor receptor (EGFR) and HER2, as a single 
agent, promotes, apoptosis in trastuzumab-resistant breast 
cancer cell lines. In these cells, its cytotoxic effect is corre-
lated with the blockade of the activation of Akt, p70 S6K, and 
MAPK.53 Furthermore, lapatinib also sensitizes HER2-positive 
breast cancer cells to other therapies such as radiation and also 
restores tamoxifen sensitivity in tamoxifen-resistant breast 
cancer models suggesting that this ability of lapatinib may 
be due to the inhibition of the PI3K-Akt signaling pathway. 
Accordingly, pre-clinical models also show that failure to 
inhibit Akt activation leads to resistance to therapies with 
TKIs against HER-family.26,55–58
Akt activity also promotes resistance to chemotherapy in 
breast cancer cell lines,54 and recent findings correlate pAkt 
levels and HER2 status with resistance to endocrine therapy 
in metastatic breast cancer.59 A retrospective study with tumor 
samples from 36 metastatic breast cancer patients treated with 
endocrine therapy showed 12 cases (33.4%) with pAkt. In the 
pAkt-positive patients, endocrine therapy proved less effica-
cious than in pAkt-negative patients (p  0.01)54 and pAkt was 
associated with a poor objective response (p  0.05). Clinical 
benefit was also lower in HER2-positive patients (P0.05) 
and was the lowest in the HER2 and pAkt-positive patients 
(p  0.01). Therefore, evidence suggests that pAkt may be a 
useful predictor of resistance to chemotherapy and endocrine 
therapy for breast cancer. These data suggest that inhibition 
of Akt activation in breast cancer patients may increase the 
efficacy of endocrine therapy and chemotherapy.
Based on the above evidence, clinical trials that explore the 
efficacy of the mTOR inhibitors temsirolimus and everolimus OncoTargets and Therapy 2009:2 142
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alone or in combination with aromatase inhibitors in hormone 
receptor positive breast cancer patients are underway.60–62
Regarding triple-negative breast cancer, one of its 
molecular features is the overexpression of genes that encode 
for the TKRs EGFR and c-KIT that lead to abundant MAPK 
and Akt signaling activation downstream. Therefore, Akt 
could be also a promising target for the treatment of triple-
negative breast cancer.46
In conclusion, these findings suggest that Akt activa-
tion should be used as a molecular marker in breast cancer 
patients to predict treatment response. The blockade of Akt 
activation in combination with current therapies may be 
also considered a novel therapeutic approach in most breast 
cancer molecular subtypes.
Non-small cell lung cancer
Pre-clinical data have shown that pAkt is also active in most 
NSCLC cell lines and that the modulation of Akt activity (by 
pharmacological or genetic approaches) sensitizes cells to 
chemotherapy and radiation.58 A correlation between pAkt 
and poor prognosis has been also established for all stages of 
NSCLC.63,64 Tang and colleagues reported that loss of PTEN 
and the presence of pAkt is correlated with poor differentia-
tion, lymph node involvement, distant metastasis, and late 
stages in NSCLC patients.65 Therefore, the combinations 
of drugs that modulate Akt activation with the therapeutic 
modalities typically used in NSCLC are thought to improve 
treatment response.
Additionally, while some authors have reported the possible 
role of pAkt as a predictive marker of response to gefitinib, 
an oral small molecule that blocks EGFR, in NSCLC patients 
with specific EGFR mutations, others have failed to find any 
association. Sordella and colleagues showed that these EGFR 
mutants selectively activate the Akt survival pathway.66 
Cappuzo and colleagues reported that gefitinib was more 
effective in patients with pAkt-positive tumors. These patients 
showed better response rates, disease control rates, and times to 
progression than patients with pAkt-negative tumors.67 Other 
authors have indicated that although no significant correlation 
between EGFR mutations and expression of pAkt was detected 
in gefitinib-treated patients, pAkt overexpression was associ-
ated with prolonged time to progression.68 Consistent with 
these findings, pre-clinical studies have shown that those EGFR 
mutations that sensitize to gefitinib selectively activated the Akt 
pathway. High sensitivity to EGFR TKIs in NSCLC seemed 
to be closely correlated with dependence on Akt activation in 
response to EGFR signaling.65,69 Therefore, further studies are 
necessary to confirm whether the assessment of pAkt status 
could be a useful complementary test for the identification of 
EGFR-positive NSCLC patients with the highest possibility 
of profiting from TKIs.
Exposure to cigarette smoke (active or passive) is the main 
cause of lung cancer.70 The presence of nicotinic acetylcholine 
receptors in NSCLC cell lines and primary tissues has been 
documented.71,72 After exposure to nicotine, Akt is phosphory-
lated in NSCLC cells. The Akt activation induced by nicotine 
leads to an increase in its downstream effectors and confers 
resistance to NSCLC cells treated with chemotherapeutic 
agents.69,71 Furthermore, it has been shown that nicotine in 
NSCLC cells promotes resistance to TKIs such as gefitinib.69
Pancreatic cancer
High levels of pAkt have been detected in 40%–70% of pan-
creatic cancers and 60% of tumors show EGFR amplification. 
Therefore, these proteins and their downstream effectors could 
be new therapeutic targets for treatment, as well as useful 
molecules for diagnosis and prognosis.73 In fact, erlotinib, 
an oral small-molecule anti-EGFR, has been approved by the 
US Food and Drug Administration (FDA) for the treatment 
of locally advanced or metastatic pancreatic cancer. EGF 
receptor-related protein (ERRP), a novel EGFR-negative 
modulator has also shown anti-tumor activity in pre-clinical 
studies through its ability to downregulate molecular markers 
such as Akt, NF-κB, and MAPK.74,75 Buck and colleagues 
also showed that the combination of the mTOR inhibitor 
rapamycin with erlotinib has anti-tumor activity in human 
pancreatic cancer cell lines that do not respond to erlotinib in 
monotherapy. These authors suggest that although erlotinib 
could not downregulate baseline Akt activity in pancreatic 
cancer-resistant cell lines, it could synergize with rapamycin 
by inhibiting the stimulated Akt activity induced by rapamy-
cin.76 Indeed, strategies aimed at blocking Akt activation could 
be promising for the treatment of pancreatic cancer.
Hormone-refractory prostate cancer
Metastatic hormone-refractory prostate cancer (HRPC) 
patients show enhanced Akt activity. Some also show loss 
of PTEN, which leads to the activation of downstream 
Akt anti-apoptotic effectors such as Bcl-xl, Bcl-2 (B-cell 
lymphoma 2), and NF-κB, and other Akt effectors such as 
mTOR/p70 S6K.77,78
The current reference treatment for HRPC consists mainly 
of chemotherapy with docetaxel. However, interference with 
cell survival, through pro-apoptotic drugs, combined with 
docetaxel is a new approach.78 Clinical trials with agents 
that reduce the expression of anti-apoptotic Bcl-2 proteins OncoTargets and Therapy 2009:2 144
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are ongoing (a phase II study with oblimersen sodium plus 
docetaxel), studies with anti-NF-κB therapies have been 
reported (phase I/II studies with thalidomide, arsenic trioxide, 
and bortezomib), and also the mTOR inhibitors (rapamycin, 
temsirolimus, and everolimus) have also produced good results 
in pre-clinical models. Nevertheless, a phase II clinical study 
with the Akt inhibitor perifosine showed poor results.76,78
Gastric cancer
In the last American Society of Clinical Oncology (ASCO) 
annual meeting, Xu and colleagues showed that 148 (78.7%) 
were positive for p-Akt among 188 gastric adenocarcinoma 
samples. High expressions of p-Akt were significantly 
correlated with pTNM stage (p = 0.031), depth of invasion 
(p  0.001), lymph node metastasis (p  0.001) and dif-
ferentiated levels (p  0.012).79
Additionally, Oki and colleagues have shown a direct 
correlation between Akt activation and chemoresistance in 
gastric cancer. Analysis of primary gastric carcinoma tis-
sue and corresponding normal mucosa from gastric cancer 
patients who underwent surgery showed that Akt activation 
and loss of PTEN were associated with increased resistance 
to several chemotherapeutic agents.80,81 A pre-clinical study 
also showed that those chemotherapeutic agents that induced 
apoptosis in human gastric cancer cell lines downregulated 
the PI3K-Akt pathway.80
Additionally, pAkt levels were associated with the effi-
cacy of some adjuvant chemotherapy regimens and indicated 
the association between pAkt levels with poor prognosis for 
T3/T4 gastric cancer patients.82
Although further studies are necessary to establish the 
predictive value of Akt signaling in sensitivity/resistance to 
gastric cancer therapies, these data suggest that drug com-
binations including Akt inhibitors may improve response in 
patients with gastric cancer.
Hepatocellular carcinoma
Alterations in the TKR c-Met have been involved in HCC 
(hepatocellular carcinoma) progression.83 In human HCC 
cell lines, hepatocyte growth factor (HGF) uses its associa-
tion with c-Met to promote the activation of the PI3K-Akt 
pro-survival pathway, which led to suppression of the pro-
apoptotic signals mediated by Fas.84 Fas is a membrane 
receptor that induces apoptosis after binding its ligand FasL 
onto the surface of T-cells. Fas/FasL signaling seems to 
mediate chemosensitivity in pre-clinical models of HCC.85 
Those HCC cell lines that respond to chemotherapy show 
increased Fas/FasL-mediated apoptosis. c-Met, through its 
ability to activate Akt, may be involved in resistance to those 
chemotherapeutic agents that mediate its cytotoxic effect by 
stimulating the Fas-FasL apoptotic pathway.
EGFR, IGF2, and its receptor IGF-1R are also detected in 
HCC cell lines and cross-talks between EGFR and IGF-1R 
have been reported in different tumor types. IGF2-IGF-1R 
activates proliferation through Ras/MAPK pathway and 
survival by means of PI3K/Akt.86,87 In fact, gefitinib alone 
was not able to completely prevent the development of HCC 
in pre-clinical models86 and IGF2-IGF-1R may contribute 
to gefitinib resistance in HCC cells through the activation 
of PI3K/Akt pathway. Treatment of HCC cell lines with 
gefitinib blocked Akt activation induced by EGFR itself, 
although gefitinib had no effects on the Akt activation 
induced by IGF2-IGF1R; therefore, it could not cause the 
death of the tumor cells by itself.
Additionally, a selective IGF-1R inhibitor was able to 
induce apoptosis in these HCC cells and its cytotoxic effect 
was boosted by gefitinib.88 Therefore, the IGF2/IGF-1R sur-
vival signal promoted by the activation of Akt may contribute 
to gefitinib resistance in HCC. In this setting, the pharmaco-
logical combination of gefitinib with anti-IGF-1R antibody 
or inhibition downstream in the pI3K-Akt pathway could 
enhance the anti-tumor effects reached by gefinitib as a single 
agent in HCC.
Brain tumors
The PI3K-Akt pathway is relevant in glioma initiation and 
progression.89 PTEN is frequently lost or mutated in high-
grade gliomas and most of these tumors have elevated Akt 
activity. Gliomas also seem to be good targets for therapies 
based on inhibitory compounds of the PI3K-Akt-p70 S6K 
pathway.
Recently, activation of the Akt pathway in 101 neuro-
blastoma samples was also tested: 60% of the tumor samples 
expressed PI3K, 80% Akt, and 73% pAkt. In addition, p70 S6K 
was expressed in 95% of tumors. Akt and pAkt also showed 
higher expression in metastases than in primary tumors.90
Akt inhibitors
As we described above, PI3K-Akt-mTOR pathway plays a 
critical role in proliferation and survival in tumor cells and 
is also linked with resistance to radiotherapy, chemotherapy, 
endocrine therapy and novel anticancer therapies.91–94 In 
this setting, this pathway seems to bring together all the 
characteristics of a good target for the treatment of cancer. 
Currently, clinical trials with inhibitors of the PI3K-Akt 
pathway in monotherapy or in combination with other anti-OncoTargets and Therapy 2009:2 145
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cancer drugs are underway in cancer patients. In addition, 
these novel inhibitors are being also tested in chemo- and 
hormonal therapy refractory patients.95,96
Although in this review we will focus on inhibitors of Akt, 
currently PI3K and mTOR inhibitors are more advanced in 
their development than Akt inhibitors. In fact, a new genera-
tion of PI3K inhibitors is emerging. Some of them, such as 
NVP-BEZ235, a synthetic low molecular weight compound 
belonging to the class of imidazoquinolins, which potently 
and reversively inhibits class I PI3K catalytic activity by 
competing with the ATP is in early phase clinical trials.97 
And as we mentioned above, the rapamycin-derivated tem-
sirolimus and everolimus, as mTOR inhibitors, have been 
already approved for the treatment of same cancer patients 
and clinical trials to explore their efficacy in new tumor types 
are currently underway.16,41,98 Furthermore, rapamycin ana-
logs lead to an increase in PI3K and Akt activation, through 
a feedback mechanism mediated by IGF-1R. Therefore, 
this Akt activation may counteract the inhibition of mTOR. 
Combined treatment with mTOR inhibitors and anti-IGF-1R 
monoclonal antibodies (MAbs) are currently being tested in 
caner patients.99 In addition, due to the cross-talk between ER 
and PI3K/Akt/mTOR pathways, clinical trials with mTOR 
inhibitors and endocrine therapy are also underway.60
In this context, the use of anti-target agents that block 
selectively each Akt isoforms or the use of dual inhibitors 
that block this pathway in two levels (pg, dual Akt-S6K small 
inhibitors, dual mTOR complex 1 and 2 inhibitors, etc) may 
improve the results reached with the current mTOR inhibi-
tors. During recent years, intense efforts made in the search 
for Akt inhibitors have yielded several promising candidates, 
such as lipid-based inhibitors that compete with PIP3 to bind 
the PH domain of Akt, ATP-competitive inhibitors, small-
molecule inhibitors, and peptide-based inhibitors reviewed 
elsewhere.100,101
The lipid-based inhibitors include perifosine (KRX-0401), 
an orally active membrane-permeable ether lipid with a 
single long alkyl chain that inhibits the translocation of all 
Akt isoforms to the membrane. In vitro, perifosine has anti-
proliferative effects in many tumor cell lines and sensitizes 
tumor cells to radiation and chemotherapy. Perifosine has 
also shown efficacy and tolerability in phase I clinical tri-
als.102 However, the lack of objective responses as a single 
agent has been observed in several recent phase II trials in 
patients with malignant melanoma, prostate cancer, head 
and neck cancer, and pancreatic adenocarcinoma.101 Phase 
II trials with perifosine combined with radiotherapy, chemo-
therapy or other anticancer agents, such as imatinib mesylate 
and trastuzumab, are ongoing.100 In the last ASCO annual 
meeting, preliminary results from a phase I study from a 
multicenter trial of perifosine plus in patients with advanced 
solid tumors were reported. Accrual is in the last cohort. To 
Table I Akt signaling deregulation in tumors.   Association with resistance to treatment
Alteration Tumor
increase in Akt protein/activity, 23%–50%114
PTeN mutation/loss, 37%115
Pi3K alteration, 4%116
Lung
increase in Akt protein/activity, 38%117
PTeN mutation/loss, 31%118
TSC1/TSC2 alteration119
Kidney
increase in Akt1 protein/activity, 24%–40%120 
increase in Akt2 protein/activity 90% erbB-2hi121 
PTeN mutation/loss, 15%–41%122
Pi3K alteration, 24–42%123
Breast
TSC1/TSC2 alteration124 Neuroendocrine tumors
increase in Akt1 protein/activity, 34%–50%125 
PTeN mutation/loss, 30%–63%126
Prostate
increase in Akt2 expression, 46%127 
PTeN mutation/loss, 35%128 
Pi3K alteration, 20%–32%128,129
Colon
High Akt activity130 Pancreas
High Akt activity131 
Loss of PTeN132,133
Gastric Cancer
High Akt activity134 
PTeN mutation/loss135
Brain TumorsOncoTargets and Therapy 2009:2 146
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date no unexpected toxicities and clinical activity has been 
noted within the first three cohorts with four of six (67%) 
evaluable patients with advanced cancer achieving at least 
stable disease for more than six months. One partial response 
has been also seen.103
Triciribine phosphate monohydrate (TCN-P; VQD-002, 
VioQuest Pharmaceuticals, Basking Ridge, NJ, USA) is an 
old anticancer agent discovered more than 35 years ago that 
was discontinued due to severe side effects at high doses. 
The discovery of triciribine as a potent and selective inhibi-
tor of Akt has led to renewed interest in its further develop-
ment. VQD-002 works as a pan-Akt inhibitor that targets 
the PH domain of Akt. It inhibits the growth of human 
tumors that overexpress Akt in mice at low doses without 
visible side effects. VQD-002 has demonstrated compelling 
preclinical activity in combination with other targeted 
therapies (trastuzumab and TKIs) in many tumor types, such 
as glioblastoma, lymphomas, refractory leukemia, breast, 
colon, NSCLC, and prostate.104 VQD-002 is in Phase I/IIa 
clinical trials in solid and hematological tumors.101
GSK690693 is an Akt ATP-pocket binder developed by 
GSK with IC50 values of 2 nM, 13 nM, and 9 nM against 
Akt1, Akt2, and Akt3, respectively.101 In vitro, GSK690693 
showed a strong additive effect in a variety of tumor cells 
when combined with other anti-target drugs such as lapatinib. 
It also showed significant efficacy in xenograft models from 
ovarian (SK-OV-3), prostate (LNCaP), and breast (BR474, 
HCC-1954) carcinoma cell lines. Phase I clinical trials in 
patients with solid tumors and lymphomas treated with 
intravenous GSK690693 are underway.105,106
XL418 is an orally active and low-nanomolar dual Akt and 
p70 S6K inhibitor developed by Exelisis Inc. (San Francisco, 
CA, USA) that also acts as an ATP-pocket binder.101 It has 
already demonstrated good in vivo efficacy in several xenograft 
models, including lung (A549) and breast adenocarcinoma 
(MCF7) tumor cell lines as a single agent or in combination 
with chemotherapeutic drugs such as paclitaxel. It has also 
been shown to enhance apoptosis in combination with TKIs 
that target EGFR, HER2, and VEGFR. A phase I clinical trial 
with this drug is ongoing.
Therefore, we can see that perifosine and VQD-002 
block Akt activation through their interaction with the PH 
domain of Akt,101 whereas GSK690693 and XL418 inhibit 
the kinase activity of the active Akt through binding to its 
ATP pocket.
Treatment with pan-Akt inhibitors has shown unexpected 
toxicity. One of these side effects includes hyperglycemia. 
GSK690693 leads to increased blood glucose and insulin 
levels, although these return to baseline levels as the 
circulating drug concentration decreases. This side effect was 
also observed in clinical trials with perifosine and triciribine 
phosphate.101 The hyperglycemia induced by these inhibitors 
is consistent with the phenotype of the Akt2 knockout mice.107 
Another pan-Akt inhibitor developed by Abbott, a series of 
3,5-disubstituted pyridines (A-443654 and A-6745639), was 
reported to cause severe hypotension in rats and dogs that 
could be partly due to inhibition of other kinases.100
Regarding the feedback mechanism mediated by IGF1-R, 
the inhibition of Akt or mTOR complex 1 leads to subse-
quent suppression of phosphorylation of p70 S6K, which 
inhibits the phosphorylation and subsequent inactivation of 
insulin receptor substrate 1 (IRS-1) by p70 S6K. Activation 
of IRS-1 promotes the insulin-stimulated activation of Akt 
via PI3K.12,101,108–110 Therefore, this Akt activation might 
attenuate the therapeutic effects reached with the mTOR 
complex 1 inhibitors, although the combination rapamycin 
analogs with therapies that simultaneously prevent subsequent 
Akt activation (pg, MAbs against IGF1-R, and others) might 
be more effective. In this sense, significant synergy between 
mTOR inhibitors and anti-TKR drugs has also been observed.101 
In fact, dual inhibition with the mTOR inhibitor everolimus 
combined with a monoclonal antibody against IGF-1R results 
in a supra-additive growth inhibitory effect both in vitro and 
in vivo in breast cancer models.13 Clinical studies with this 
combination in breast cancer patients are planned.
The search for small molecule inhibitors that interact with 
the allosteric site of Akt represents a new frontier in drug 
discovery. In this regard, Merck and Co, Inc. (Whitehouse 
Station, NJ, USA) has synthesized allosteric isoform-selective 
Akt inhibitors that are able to inhibit Akt kinase activity (like 
the ATP pocked binders) and in addition the activation of Akt 
by phosphorylation.101 In this setting, the activation of Akt 
via the feedback mechanism would be abolished. Therefore, 
these allosteric Akt inhibitors should be more efficient than 
the ATP-pocket binders in attenuating Akt activity. However, 
preliminary studies have revealed that the effect of single 
isoform inhibition is not superior to the simultaneous inhibi-
tion of Akt1 and Akt2 with pan-Akt inhibitors.101
Another trend in this area is the search for novel Akt 
inhibitors that bind to other sites of Akt, based on the fact 
that activity and function of Akt are also regulated by many 
interacting proteins.101 Akt-in is a peptide composed of 
15 amino acids designed to mimic the interaction between 
Akt and a physiological coactivator, T-cell leukemia/
lymphoma 1 (TCL1). The Akt-in sequence encompasses a 
portion of the TCL1 protein that binds Akt in its PH domain OncoTargets and Therapy 2009:2 147
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and inhibits Akt kinase activity and membrane translocation 
in cell lines. It also inhibits tumor cell proliferation in 
preclinical models but has poor oral bioavailability and 
cellular penetration. Other approaches use the consensus 
protein sequence preferred by Akt to develop pseudopeptide 
substrates that have been shown to inhibit Akt and the growth 
of cancer cells in vitro.111,112
Akt antisense inhibitors that block Akt translation are 
also being developed. RX-0201 is a 20-mer oligonucleotide 
with a sequence complementary to that of Akt-1 mRNA that 
inhibits the expression of Akt-1 in tumor cell lines and bears 
significant in vitro and in vivo anticancer activity with good 
safety. A phase I trial with RX-0201 that aimed to determine 
the maximum tolerated dose and pharmacokinetic and safety 
profile of RX-0201 was reported at the last ASCO meeting 
and phase II clinical trials are being planned.113
Summary
A more in-depth knowledge of the molecular pathogenesis 
of cancer has led to the discovery of new tumor targets. 
These are aimed at targets located on the cell membrane and 
inside the cell. The newly approved target-based anticancer 
agents (erlotinib, gefitinib, lapatinib, trastuzumab, cetuximab, 
sunitinib, sorafenib, imatinib, dasatinib, and temsirolimus) 
have not only shown efficacy in terms of response rate and 
progression-free survival, but also a good safety profile.
The PI3K/Akt pathway emerges as one of the most 
promising targets in the immediate future. Pharmaceutical 
companies are developing new agents against this pathway. 
Hopefully, these new agents will become part of the anti-
tumor armamentarium.
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